INTRODUCTION TO BIOMARKERS - Flow Cytometry in Drug Discovery and Development - page 65

25. Seymour AA, Benoni EA, Smith PL, Mathers PD, AsaadMM, RogersWL. Potentiation of
natriuretic peptides by neutral endopeptidase inhibitors. Clin. Exp. Pharmacol. Physiol.
1995;22:63-69.
26. ICHHarmonised Tripartite Guideline Validation of Analytical Procedures: Methodology,
November 6, 1996.
27. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller
KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method
validation—a revisit with a decade of progress. Pharm. Res. 2000;12:1551-1557.
28. DeSilva B, SmithW, Wiener R. Recommendations for the bioanalytical method validation
of ligand-binding assays to support pharmacokinetic assessments of macromolecules.
Pharm. Res. 2003;20:1885-1900.
29. Owens MA, Vall HG, Hurley AA, Wormsley SB. Validation and quality control of
immunophenotyping in clinical flow cytometry. J. Immunol. Methods 2000;243:33-50.
30. Swanson B. Delivery of high-quality biomarker assays. Dis. Markers 2002;18:47-56.
31. Vesterqvist O. Using pharmacodynamic biomarkers to accelerate early clinical drug
development. In Ilyin S, editor. Functional Informatics in Drug Discovery, CRC Press,
Boca Raton, FL, 2008, pp.41-53.
32. Goulart BHL, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the
use and role of biomarkers in phase I oncology trials. Clin. Cancer Res.

2007;13:6719-6726.
33. Ratain JM, Glassman HR. Biomarkers in phase I oncology trials: signal, noise, or
expensive distraction? Clin. Cancer Res. 2007;13(22):6545-6548.
34. Green K, Vesterqvist O. Drug interactions with the in vivo synthesis of thromboxane and
prostacyclin. Drug Metab. Drug Interact. 1989;7:321-350.
35. Katz A, Chandrasekhar U, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O,
Meng X. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623,
a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharmacol.

2009;49:643-649.
36. Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal
variation that is asynchronous with cholesterol synthesis. Gastroenterology

2005;129:1445-1453.
37. Krams M, Bruman CF, Dragalin V, Gaydos B, Grieve AP, Pinheiro J, Maurer W, Gallo P.
Adaptive designs in clinical drug development: opportunities, challenges, and scope
reflections following PhRMA's November 2006 workshop. J. Biopharm. Stat.
2007;17:957-964.
38. Brown CH, Ten Have TR, Jo B. Adaptive designs for randomized trials in public health.
Annu. Rev. Public Health 2009;30:1-25.
39. Vesterqvist O, Reeves R. Effects of omapatrilat on pharmacodynamic biomarkers of
neutral endopeptidase and angiotensin converting enzyme activity in humans. Curr.
Hypertens. Rep. 2001;3 (Suppl. 2):22-27.
40. Vesterqvist O. Measurements of the in vivo synthesis of thromboxane and prostacyclin
in humans. Scand. J. Clin. Lab. Invest. 1988;48:401-407.